Loss of chromosome Y in hematopoietic cells: mechanisms and implications for human disease
Peer-Reviewed Publication
Updates every hour. Last Updated: 28-Oct-2026 22:17 ET (29-Oct-2026 02:17 GMT/UTC)
Hematopoietic loss of chromosome Y (LOY) has emerged as one of the most prevalent somatic genomic alterations in aging males, yet its biological significance extends far beyond a mere marker of aging. This comprehensive review synthesizes current understanding of LOY, from its molecular origins in mitotic chromosome mis-segregation to its far-reaching clinical implications. Advances in detection technologies, including single-cell sequencing and bulk genomic approaches, have enabled robust identification of LOY across population scales. The review examines how inherited genetic variation, environmental exposures, and aging collectively contribute to LOY pathogenesis. Large-scale genome-wide association studies have revealed compelling epidemiological links between hematopoietic LOY and cardiovascular disease, neurodegenerative conditions, immune disorders, and cancer. Mechanistically, LOY drives altered gene expression, immune dysregulation, and clonal expansion of affected hematopoietic cells. Critically, CRISPR-based mouse and cellular models have recapitulated key disease phenotypes, establishing LOY as a functionally consequential form of somatic mosaicism with profound implications for disease susceptibility and male health disparities.
CAMBRIDGE, Mass., September 2 - Insilico Medicine (“Insilico”; HKEX: 3696), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today announced the release of a series of frontier specialist models for chemistry and biology, trained through its MMAI Gym for Science framework. Across chemistry and biology, the models demonstrate state-of-the-art (SOTA) performance on more than 50 benchmark tasks.
Boston University sociologist Sarah Miller discusses her new book on teen bullying, social media, and why schools need to rethink anti-bullying efforts.
A real-world study of 145 resectable NSCLC patients who achieved pathological complete response after neoadjuvant chemoimmunotherapy found no significant disease-free or overall survival benefit from adding adjuvant immunotherapy. The findings suggest that patients with a pCR may not need further postoperative treatment, though larger prospective studies are required for confirmation.
A research team from Fujita Health University, Japan, engineered a lab-grown model of heart failure with preserved ejection fraction (HFpEF), where the heart’s relaxation function is impaired. Human induced pluripotent stem cell-derived tissues were cultured in a medium with abundant fatty acids and L-NG-nitroarginine methyl ester. This model was used to study HFpEF’s underlying disease processes and treatment options. Among the current treatment options tested, the antidiabetic SGLT2 inhibitors showed improvement in relaxation function.
Scientists at Peking University have identified a mitochondrial protein that is essential for protecting motor neurons, offering new insight into how amyotrophic lateral sclerosis (ALS) may develop. The study, led by Dr. Xianhua Wang and Dr. Heping Cheng at the College of Future Technology, Peking University, shows that loss of the mitochondrial protein ROMO1 causes progressive damage to motor neurons and muscles in mice, closely resembling key features of human ALS. The findings were published online in Science Bulletin.